XORTX Therapeutics Inc. (NASDAQ:XRTX) Stock Short Interest Report for October

XORTX Therapeutics Inc. (NASDAQ:XRTX) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totaling 237,048 shares, an increase of 285.2% from the September 30th total of 61,535 shares. Based on an average daily volume of 2,819,981 shares, the days-to-cover ratio is presently 0.1 days. Currently, 14.0% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XORTX Therapeutics in a research report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has a consensus rating of “Sell”.

XORTX Therapeutics Price Performance

NASDAQ XRTX opened at $0.97 on Thursday. XORTX Therapeutics has a 1-year low of $0.83 and a 1-year high of $3.60. The business has a 50 day simple moving average of $1.77 and a two-hundred day simple moving average of $2.15. The stock has a market capitalization of $1.77 million, a PE ratio of -0.39 and a beta of 0.78.

XORTX Therapeutics (NASDAQ:XRTX) last released its earnings results on Saturday, August 15th. The technology company reported ($1.05) earnings per share (EPS) for the quarter.

About XORTX Therapeutics

XORTX Therapeutics Inc (NASDAQ:XRTX) is a clinical-stage pharmaceutical company focused on developing therapies for conditions associated with dysregulated uric acid metabolism. The company’s research is centered on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of addressing kidney and other serious chronic diseases.

XORTX’s development programs include XRx-008, an orally administered therapy being developed for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function.